Hosted on MSN12d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its HandsAnd regarding the slower-than-expected sales in the industry, Novo Nordisk's work goes beyond diabetes and obesity, which are ...
Hosted on MSN16d
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its useThe Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's ...
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback